MorphoSys Announces Three New Clinical Milestones
MARTINSRIED, GERMANY and MUNCHEN, GERMANY–(Marketwire – Dec 10, 2010) –
MorphoSys AG /
MorphoSys Announces Three New Clinical Milestones
Processed and transmitted by Thomson Reuters.
The issuer is only obliged for the calm of this announcement.
Three Partners Bring HuCAL Antibodies in to Clinical Trials: All Six
Partnered
Clinical Milestones Expected for 2010 Achieved
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) voiced today
that
three of the partners have filed applications for proviso 1 clinical trials
with
HuCAL antibodies. In any case, the filing of the focus triggers an
undisclosed miracle remuneration to MorphoSys. The healing antibodies are
being
developed in the healing areas of cancer and inflammatory diseases.
Today’s
announcement brings to 6 the series of HuCAL antibodies which have entered
clinical growth in 2010. Details on the particular programs will be
published as the particular trials commence.
“This has been an superb year for swell in the pipeline,” commented
Dr.
Marlies Sproll, Chief Scientific Officer of MorphoSys AG. “The series of
partnered HuCAL antibody programs in the hospital has roughly doubled – from
seven
at the finish of final year to thirteen now. With the 3 brand brand new starts announced
today,
seven opposite partners from the curative and biotechnology industry
are
currently using clinical trials with the antibodies. Milestone payments
from
these programs have been an critical source of income for MorphoSys. Even more
importantly, we have been office building estimable long-term worth for the association as
programs allege in to and by clinical development.”
With today’s news, a sum of 6 HuCAL-derived antibodies have advanced
into
human clinical trials in 2010: the 3 voiced now together with two
programs from the fondness with Novartis and one from Centocor Ortho
Biotech. As
a result, MorphoSys’s clinical tube now comprises 8 partnered
programs in Phase 1 and 5 in Phase 2 growth as good as the
Company’s
proprietary programs MOR103, which is in a Phase 1b/2a hearing for rheumatoid
arthritis, and MOR208, which is in a Phase 1 hearing for cancer.
About MorphoSys:
MorphoSys is an eccentric biotechnology association which develops novel
antibodies
for therapeutic, evidence and investigate applications. The Company’s HuCAL
technology is one of the many absolute methods accessible for generating
fully
human antibodies. By successfully requesting this and alternative proprietary
technologies, MorphoSys has turn a personality in the margin of therapeutic
antibodies, one of the fastest-growing drug classes in tellurian health-care.
Through the alliances with a little of the world’s heading pharmaceutical
companies,
MorphoSys has combined a tube of some-more than 60 drug candidates. The
Company is
expanding the drug tube by adding brand brand new partnered programs, and by
building a
portfolio of fully-owned healing antibodies. For the proprietary
portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced module MOR103, a first-in-class, entirely tellurian antibody opposite GM-
CSF,
is now being tested in a Phase Ib/IIa hearing in rheumatoid arthritis
patients. Via the commercial operation section AbD Serotec, MorphoSys is expanding the
reach of
its technologies in the diagnostics and investigate markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the pitch “MOR”. For serve information,
visithttp://www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and
RapMAT® have been registered
trademarks of MorphoSys.
This report exchnage contains sure forward-looking statements concerning
the
MorphoSys organisation of companies. The forward-looking statements contained
herein
represent the visualisation of MorphoSys as of the date of this recover and
involve
risks and uncertainties. Should tangible conditions talk about from the Company’s
assumptions, tangible formula and actions might talk about from those anticipated.
MorphoSys does not intend to refurbish any of these forward-looking statements
as
far as the diction of the germane press recover is concerned.
— End of Message —
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All
Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release (PDF):
http://hugin.info/130295/R/1471133/407968.pdf
This proclamation is distributed by Thomson Reuters on interest of
Thomson Reuters clients. The owners of this proclamation warrants that:
(i) the releases contained herein have been stable by copyright and
alternative germane laws; and
(ii) they have been only obliged for the content, correctness and
newness of the report contained therein.
Source: MorphoSys AG around Thomson Reuters ONE
[HUG#1471133]
